Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Gross Profit (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Gross Profit for 15 consecutive years, with $21.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Gross Profit rose 19.27% to $21.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $83.2 million, a 35.08% increase, with the full-year FY2025 number at $83.2 million, up 35.08% from a year prior.
  • Gross Profit was $21.7 million for Q4 2025 at Niagen Bioscience, down from $21.9 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $21.9 million in Q3 2025 to a low of $9.2 million in Q1 2021.
  • A 5-year average of $14.0 million and a median of $12.6 million in 2023 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: decreased 7.1% in 2022, then soared 47.71% in 2025.
  • Niagen Bioscience's Gross Profit stood at $10.9 million in 2021, then increased by 10.56% to $12.0 million in 2022, then grew by 7.66% to $12.9 million in 2023, then skyrocketed by 40.66% to $18.2 million in 2024, then grew by 19.27% to $21.7 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Gross Profit are $21.7 million (Q4 2025), $21.9 million (Q3 2025), and $20.2 million (Q2 2025).